The good, the bad, and the ugly about direct-to-consumer advertising.
Jun 2, 2008
By:
Michelle Hoffman
The good, the bad, and the ugly about direct-to-consumer advertising.
|
Creating a kinder, gentler manufacturing process that doesn't kill the product is the goal of process developers doing large-scale cell culture for cell therapy.
Jun 2, 2008
By:
Michelle Hoffman
Creating a kinder, gentler manufacturing process that doesn't kill the product is the goal of process developers doing large-scale cell culture for cell therapy.
|
Scientists are giving up on a preventive vaccine for AIDS, but there are lessons to be learned.
May 2, 2008
By:
Michelle Hoffman
Scientists are giving up on a preventive vaccine for AIDS, but there are lessons to be learned.
|
Apr 2, 2008
By:
Michelle Hoffman
Antibodies are highly specific molecules that can be tailored to recognize almost any stretch of peptide that nature can conjure: a feature that has been exploited for years now to produce therapeutic antibodies.
|
The FDA itself issues a cry for help. Is anybody listening?
Apr 2, 2008
By:
Michelle Hoffman
The FDA itself issues a cry for help. Is anybody listening?
|
Feb 2, 2008
By:
Michelle Hoffman
Text sirtuins are the new kinases, according to a presentation given last month at the JP Healthcare Investors Conference in San Francisco by Sirtis CEO Christoph Westphal.
|
Can an overload of patent applications lead to the US' demise as a scientific leader?
Feb 2, 2008
By:
Michelle Hoffman
Can an overload of patent applications lead to the US' demise as a scientific leader?
|
Fixing FDA lies in the hands of the government, but is the president-to-be paying attention?
Jan 2, 2008
By:
Michelle Hoffman
Fixing FDA lies in the hands of the government, but is the president-to-be paying attention?
|
|
